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Opportunity and cost of
sevelamer in dialysis
patients
To the Editor: Manns et al [1] have recently pointed
out the high cost of replacing by sevelamer, the calcic
phosphate-binder, and the higher prevalence of patients
who would necessitate sevelamer according to K/DOQI
guidelines in America than in Canada, and in hemodialy-
sis patients (66% vs. 54%) than in peritoneal dialysis pa-
tients (60% vs. 38% in U.S. and Canadian patients, respec-
tively). These differences suggest us that it may be due to
higher prevalence of 1 a OH vitamin D use and, more pre-
cisely, of intravenous Calcijex or Zemplar in the U.S.
because of the Medicare reimbursement policy, with only
drugs given during the dialysis session being reimbursed.
Indeed, the Teng Cohort Study [2] pointed out than within
a year, the prevalence of hypercalcemia increased from
6.7% to 8.2%, and that of hyperphosphatemia increased
from 11.9% to 13.9%. This suggests, therefore, that to de-
crease the cost of Ca-phosphate-binder replacement by
sevelamer, the first measure to take would be to prevent
vitamin D insufficiency (thanks to an S 25 OH vitamin
D ≥30 ng/mL as recommended in the K/DOQI), and to
decrease the use of 1 a OH vitamin D mainly by system-
atically not using a dialysate calcium of 1.25 mmol/L, a
concentration known for 31 years to stimulate PTH secre-
tion [3], but rather, using the 1.5 mmol/L concentration
recommended by Argiles [4].
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Economic impact of sevelamer
in patients with ESRD
To the Editor: We read with interest the excellent and
timely article by Manns et al on the economic impact
of the use of sevelamer in ESRD patients [1]. Unfor-
tunately, the authors were unable to include the Cal-
cium Acetate Renagel Evaluation (CARE) study in their
pharmacoeconomics analysis because it was published af-
ter their cut-off date [2]. Likewise, results of the CARE
study were not available during the development of the
current K/DOQI clinical practice guidelines for Bone
Metabolism and Disease in Chronic Kidney Disease
[3].
Given the enormous financial burden of caring for the
ever-increasing dialysis population, it is imperative that
two criteria be met before expanding Medicare benefits to
cover the cost of sevelamer: (1) sevelamer must be shown
to be at least as effective as calcium acetate in achieving
K/DOQI guidelines for serum phosphorus and Ca × P
product; and (2) sevelamer should have documented ben-
eficial effects on the rates of hospitalization and mortality.
Unfortunately, sevelamer has not been shown to meet ei-
ther of these two criteria. In the CARE study, calcium
acetate was clearly more efficacious than sevelamer as a
phosphate binder [2]. Because uncontrolled hyperphos-
phatemia is associated with a number of clinical conse-
quences [4], use of more effective phosphate binders may,
in fact, be associated with lower overall health care cost.
Finally, because the alleged link between calcium load-
ing from use of calcium-based phosphate binders and
cardiovascular calcification has not been substantiated
in well-designed controlled trials, the argument for the
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preferential use of sevelamer in dialysis patients cannot
be justified.
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Body mass index and survival
differences in dialysis patients
To the Editor: Stack et al [1] have raised an interesting
question whether obesity may confer a survival advan-
tage or disadvantage in specific dialysis populations. The
authors have demonstrated that, unlike peritoneal dialy-
sis patients (PD), an improved survival is associated with
a greater body mass index (BMI) in hemodialysis patients
(HD) [1]. We wish to offer some supplementary reflec-
tions and suggestions regarding this issue, based on our
experience and practice.
In the general population, an increased BMI is associ-
ated with higher mortality; more properly, total mortality
is a linear increasing function of high fat mass (FM) and
low fat free mass (FFM) [2]. On the contrary, an inverse
BMI-mortality relationship has been reported in HD [3],
although the protective effect of high BMI is limited to pa-
tients with normal or high muscle mass [4]. On the other
hand, a loss of FFM may be undetected if merely BMI is
considered. We observed, in fact, that HD patients with
higher BMI, unlike healthy subjects, show a lower FFM
associated with an increased FM [5] (Table 1).
In PD, peritoneal protein loss, appetite reduction, and
presence of peritonitis may often induce a higher preva-
lence of malnutrition, as compared with HD, and a more
significant loss of FFM. A frequent increase of FM, sec-
ondary to glucose gain, may nevertheless replace the re-
duced FFM without BMI modification. These changes in
body composition, and a more unfavorable lipid profile,
may contribute to the increased mortality in PD patients
with higher BMI.
In conclusion, because BMI cannot differentiate
whether weight change is due to variation of FM or FFM,
BMI must be considered only a limitative predictive fac-
tor for survival analysis in dialysis patients; easy and
noninvasive bodycomposition methods (such as skin-fold
measurements and bioelectrical impedance analysis) are
recommended for a more accurate evaluation of the re-
lationship between BMI and mortality.
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